Based on the absence of therapeutic options for HER2-overexpressing ovarian cancer, this study aimed to determine the anticancer efficacy of samfenet, a biosimilar compound of trastuzumab, combined with NK cells in preclinical models. This evidence concerns the gene ERBB2 and ovarian cancer.